Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742609 | 0.88 | MAPT (0.51) | MAPTSIGMAR1 | |
| SCHEMBL3327622 | 0.84 | SIGMAR1 (0.53) | MAPTSIGMAR1 | |
| SCHEMBL3327616 | 0.84 | SIGMAR1 (0.53) | MAPTSIGMAR1 | |
| SCHEMBL3330369 | 0.84 | SIGMAR1 (0.53) | MAPTSIGMAR1 | |
| SCHEMBL1190075 | 0.83 | SIGMAR1 (0.57) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL1189176 | 0.83 | SIGMAR1 (0.57) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL6741206 | 0.83 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL27979641 | 0.83 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL4048121 | 0.83 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL25154582 | 0.82 | MAPT (0.50) | MAPTSIGMAR1PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | MAPT 4508/4885SIGMAR1 2945/4885PDK1 546/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | MAPT 4456/4885SIGMAR1 1138/4885PDK1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.